Med Ed 101

AUGUST 9, 2023

After being heralded as the next savior in weight loss by the media, the GLP-1 Agonists/GIP agonists have come under more scrutiny lately in the news. A recent article on CNN details patients who […] The post GLP-1 Agonists and Gastroparesis appeared first on Med Ed 101.

98

98

The Checkup by Singlecare

FEBRUARY 8, 2024

Drug interactions | Food interactions | Other interactions | Avoiding interactions | When to see a doctor Mounjaro (tirzepatide) is gaining popularity as a treatment for Type 2 diabetes mellitus and off-label for weight management. There are some contraindications with Mounjaro, such as when it should not be used and situations that require caution.

Labelling 98

Labelling Adverse Reactions Mayo Clinic FDA 98

The Checkup by Singlecare

NOVEMBER 9, 2023

It’s a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Comparable drugs Wegovy and Ozempic (semaglutide) are GLP-1 agonists that target receptors and stimulate insulin production. What is Zepbound? mg, 5 mg, 7.5 mg, 10 mg, 12.5

FDA 120

FDA Insurance Labelling 120

Hospital Pharmacy Europe

OCTOBER 12, 2023

In an analysis published in the Journal of the American Medical Association , use of semaglutide and liraglutide for weight loss was associated with an increased risk of pancreatitis, bowel obstruction and gastroparesis, compared with patients taking other weight-loss drug bupropion-naltrexone.

Medical Records 52

Medical Records Hospitals 52

PharmaShots

FEBRUARY 22, 2023

Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. mL, 3 mg/0.5 Patients can fill out an online application form.

Insurance 64

Insurance Compounding Dosage Communication 64